Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
21 05 2020
Historique:
received: 27 08 2019
accepted: 13 02 2020
pubmed: 5 3 2020
medline: 10 2 2021
entrez: 5 3 2020
Statut: ppublish

Résumé

Hemophilia A, an X-linked bleeding disorder caused by deficiency of factor VIII (FVIII), is treated by protein replacement. Unfortunately, this regimen is costly due to the expense of producing recombinant FVIII as a consequence of its low-level secretion from mammalian host cells. FVIII expression activates the endoplasmic reticulum (ER) stress response, causes oxidative stress, and induces apoptosis. Importantly, little is known about the factors that cause protein misfolding and aggregation in metazoans. Here, we identified intrinsic and extrinsic factors that cause FVIII to form aggregates. We show that FVIII forms amyloid-like fibrils within the ER lumen upon increased FVIII synthesis or inhibition of glucose metabolism. Significantly, FVIII amyloids can be dissolved upon restoration of glucose metabolism to produce functional secreted FVIII. Two ER chaperone families and their cochaperones, immunoglobulin binding protein (BiP) and calnexin/calreticulin, promote FVIII solubility in the ER, where the former is also required for disaggregation. A short aggregation motif in the FVIII A1 domain (termed Aggron) is necessary and sufficient to seed β-sheet polymerization, and BiP binding to this Aggron prevents amyloidogenesis. Our findings provide novel insight into mechanisms that limit FVIII secretion and ER protein aggregation in general and have implication for ongoing hemophilia A gene-therapy clinical trials.

Identifiants

pubmed: 32128578
pii: S0006-4971(20)62017-1
doi: 10.1182/blood.2019002867
pmc: PMC7243144
doi:

Substances chimiques

Amyloid 0
Hemostatics 0
Molecular Chaperones 0
Sweetening Agents 0
F8 protein, human 839MOZ74GK
Factor VIII 9001-27-8
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1899-1911

Subventions

Organisme : NIA NIH HHS
ID : R01 AG062190
Pays : United States
Organisme : NIDDK NIH HHS
ID : R24 DK110973
Pays : United States
Organisme : NIDDK NIH HHS
ID : R37 DK042394
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA030199
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK103185
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK113171
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA198103
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 by The American Society of Hematology.

Références

Cell Microbiol. 2008 Sep;10(9):1775-86
pubmed: 18433465
Nature. 1984 Nov 22-28;312(5992):342-7
pubmed: 6438528
EMBO J. 1996 Apr 1;15(7):1495-506
pubmed: 8612572
J Biol Inorg Chem. 1999 Oct;4(5):579-87
pubmed: 10550686
Blood. 2014 Jun 12;123(24):3697-705
pubmed: 24719406
Science. 1994 Sep 2;265(5177):1464-7
pubmed: 8073293
J Thromb Haemost. 2005 Sep;3(9):2022-31
pubmed: 16102109
J Thromb Haemost. 2014 Jan;12(1):36-42
pubmed: 24118899
J Biol Chem. 1988 May 5;263(13):6352-62
pubmed: 3129422
J Biol Chem. 1999 Oct 15;274(42):29850-7
pubmed: 10514465
Biochemistry. 2000 Feb 29;39(8):1973-81
pubmed: 10684647
Nat Commun. 2017 Oct 31;8(1):1201
pubmed: 29084938
Elife. 2015 Oct 16;4:e08961
pubmed: 26473973
J Chem Biol. 2010 Mar;3(1):1-18
pubmed: 19693614
PLoS One. 2018 Jul 19;13(7):e0201182
pubmed: 30024984
J Biol Chem. 2018 Dec 21;293(51):19659-19671
pubmed: 30355736
J Biol Chem. 1995 Apr 28;270(17):10297-303
pubmed: 7730335
Mol Biol Cell. 2013 Sep;24(17):2597-608
pubmed: 23864712
J Biol Chem. 1989 Dec 5;264(34):20602-7
pubmed: 2511206
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16863-8
pubmed: 20826442
J Cell Biol. 1987 Dec;105(6 Pt 1):2665-74
pubmed: 3121636
Nature. 1965 May 15;206(985):737-8
pubmed: 4157926
Blood. 2008 Feb 1;111(3):1240-7
pubmed: 17965321
Nature. 1989 Nov 9;342(6246):207-8
pubmed: 2509944
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):197-201
pubmed: 24344300
Methods Enzymol. 1999;309:375-86
pubmed: 10507036
Nature. 2016 Jan 21;529(7586):326-35
pubmed: 26791723
Mol Cell. 2016 Sep 1;63(5):739-52
pubmed: 27546788
Elife. 2019 Dec 17;8:
pubmed: 31845888
N Engl J Med. 2000 Aug 17;343(7):457-62
pubmed: 10950667
Proc Natl Acad Sci U S A. 1987 Jul;84(14):4846-50
pubmed: 3110773
Biochim Biophys Acta. 2013 Jan;1834(1):65-70
pubmed: 22944394
J Biol Chem. 1997 Sep 26;272(39):24121-4
pubmed: 9305856
Nature. 2006 Oct 5;443(7111):548-52
pubmed: 17024087
Science. 2011 Nov 25;334(6059):1081-6
pubmed: 22116877
Proc Jpn Acad Ser B Phys Biol Sci. 2015;91(9):469-80
pubmed: 26560836
Mol Ther Methods Clin Dev. 2016 Sep 28;3:16064
pubmed: 27738645
J Exp Med. 2009 Oct 26;206(11):2429-40
pubmed: 19808260
Blood. 2009 Jan 22;113(4):797-806
pubmed: 18957684
Br J Haematol. 2012 Jun;157(6):653-63
pubmed: 22530883
Science. 2008 Jul 25;321(5888):569-72
pubmed: 18653895
Cell. 2017 Sep 21;171(1):179-187.e10
pubmed: 28890085
Cancer Cell. 2014 Sep 8;26(3):331-343
pubmed: 25132496
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18525-30
pubmed: 19011102
J Biol Chem. 1997 Oct 24;272(43):27428-34
pubmed: 9341195
J Biol Chem. 1994 Jun 24;269(25):17329-37
pubmed: 8006042
Proc Natl Acad Sci U S A. 1990 Oct;87(19):7429-32
pubmed: 2120699
Mol Biol Cell. 2008 Jun;19(6):2620-30
pubmed: 18400946
N Engl J Med. 2017 Dec 28;377(26):2519-2530
pubmed: 29224506
Nat Biotechnol. 2004 Oct;22(10):1302-6
pubmed: 15361882
Structure. 2008 Apr;16(4):597-606
pubmed: 18400180
Mol Ther Methods Clin Dev. 2016 Sep 28;3:16063
pubmed: 27738644
EMBO J. 1992 Apr;11(4):1563-71
pubmed: 1373378
Nature. 1984 Nov 22-28;312(5992):337-42
pubmed: 6438527

Auteurs

Juthakorn Poothong (J)

Degenerative Diseases Program and.

Anita Pottekat (A)

Degenerative Diseases Program and.

Marina Siirin (M)

Degenerative Diseases Program and.

Alexandre Rosa Campos (AR)

Proteomics Core Facility, Sanford Burnham Prebys (SBP) Medical Discovery Institute, La Jolla, CA.

Adrienne W Paton (AW)

Research Centre for Infectious Diseases, Department of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA, Australia; and.

James C Paton (JC)

Research Centre for Infectious Diseases, Department of Molecular and Biomedical Science, University of Adelaide, Adelaide, SA, Australia; and.

Jacqueline Lagunas-Acosta (J)

Degenerative Diseases Program and.

Zhouji Chen (Z)

Degenerative Diseases Program and.

Mark Swift (M)

Immunity and Pathogenesis Program, SBP Medical Discovery Institute, La Jolla, CA.

Niels Volkmann (N)

Immunity and Pathogenesis Program, SBP Medical Discovery Institute, La Jolla, CA.

Dorit Hanein (D)

Immunity and Pathogenesis Program, SBP Medical Discovery Institute, La Jolla, CA.

Jing Yong (J)

Degenerative Diseases Program and.

Randal J Kaufman (RJ)

Degenerative Diseases Program and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH